Charles River Laboratories International, Inc. Q4 2025 Earnings Call Summary

Moby Intelligence

Wed, February 18, 2026 astatine 11:33 AM CST 3 min read

• Performance stabilization successful 2025 was driven by planetary biopharma clients resuming pipeline urgency aft 2024 spending pauses, alongside a late-year surge successful biotech funding.

• DSA conception request showed non-linear recovery, with nett book-to-bill improving to 1.12x successful Q4, chiefly fueled by tiny and mid-sized biotech clients.

• Management attributed Q4 borderline unit to higher-than-anticipated NHP survey demand, which forced costly open-market sourcing to fulfill lawsuit requirements.

• The acquisition of KF Cambodia is simply a strategical determination to internalize the NHP proviso chain, aiming to unafraid astir aboriginal yearly requirements and trim volatile sourcing costs.

• Discovery Services measurement declines impacted DSA revenue, portion pricing and premix remained unchangeable crossed the broader segment.

• Manufacturing conception maturation was hindered by the nonaccomplishment of a large commercialized compartment therapy client, though Microbial Solutions maintained beardown show crossed each investigating platforms.

• Management views New Approach Methodologies (NAMS) and AI arsenic semipermanent enabling technologies alternatively than contiguous disruptors to regulated information appraisal environments.

• Guidance assumes a instrumentality to integrated gross maturation successful the 2nd fractional of 2026 for some the DSA conception and the consolidated company.

• Operating borderline enlargement is predicated connected the KF Cambodia acquisition, which is expected to lend much than 100 ground points to DSA margins for the afloat year, with the borderline betterment opening to materialize successful the 2nd half.

• The 2026 model includes astatine slightest $100,000,000 successful incremental outgo savings to offset yearly outgo ostentation and support margins during the gross recovery.

• RMS gross is projected to diminution astatine a low-to-mid-single-digit complaint owed to the timing of NHP shipments and subdued CRADL occupancy from early-stage biotech.

• Capital allocation volition pivot toward indebtedness repayment and maintaining 'dry powder' for M&A successful areas similar bioanalysis and geographic enlargement into China.

• A planned divestiture of businesses representing 7% of 2025 gross is underway, with an expected $0.10 per stock accretion for the partial twelvemonth 2026.

• The CEO modulation successful 2026 volition effect successful a $0.15 EPS headwind successful Q1 owed to the required acceleration of banal compensation expenses.

• The 2026 taxation complaint is expected to driblet to 22%-23% pursuing the enactment of the 'One Big Beautiful Bill Act' (OB3) and favorable geographic mix.

• Free currency travel is projected to alteration to $375M-$400M successful 2026, impacted by higher performance-based bonus payments and CEO retirement-related deferred compensation.